Chicago Partners Investment Group LLC Purchases 319 Shares of Becton, Dickinson and Company (NYSE:BDX)

Chicago Partners Investment Group LLC lifted its position in shares of Becton, Dickinson and Company (NYSE:BDX) by 24.4% in the third quarter, HoldingsChannel.com reports. The fund owned 1,628 shares of the medical instruments supplier’s stock after buying an additional 319 shares during the period. Chicago Partners Investment Group LLC’s holdings in Becton, Dickinson and Company were worth $392,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds also recently made changes to their positions in the company. Ameriprise Financial Inc. lifted its holdings in shares of Becton, Dickinson and Company by 6.4% during the 2nd quarter. Ameriprise Financial Inc. now owns 5,055,354 shares of the medical instruments supplier’s stock worth $1,181,483,000 after acquiring an additional 302,893 shares during the period. Massachusetts Financial Services Co. MA increased its position in Becton, Dickinson and Company by 1.8% during the 2nd quarter. Massachusetts Financial Services Co. MA now owns 4,905,114 shares of the medical instruments supplier’s stock worth $1,146,374,000 after purchasing an additional 87,230 shares in the last quarter. Bank of New York Mellon Corp increased its position in Becton, Dickinson and Company by 8.5% during the 2nd quarter. Bank of New York Mellon Corp now owns 4,412,163 shares of the medical instruments supplier’s stock worth $1,031,167,000 after purchasing an additional 346,720 shares in the last quarter. Clearbridge Investments LLC increased its position in Becton, Dickinson and Company by 3.1% during the 2nd quarter. Clearbridge Investments LLC now owns 2,984,524 shares of the medical instruments supplier’s stock worth $697,513,000 after purchasing an additional 89,157 shares in the last quarter. Finally, First Eagle Investment Management LLC increased its position in Becton, Dickinson and Company by 32.5% during the 2nd quarter. First Eagle Investment Management LLC now owns 2,803,255 shares of the medical instruments supplier’s stock worth $655,149,000 after purchasing an additional 688,296 shares in the last quarter. Institutional investors own 86.97% of the company’s stock.

Becton, Dickinson and Company Trading Down 0.4 %

NYSE:BDX opened at $234.33 on Tuesday. The firm’s fifty day moving average is $237.52 and its 200-day moving average is $235.10. The company has a debt-to-equity ratio of 0.70, a quick ratio of 1.36 and a current ratio of 1.85. Becton, Dickinson and Company has a 52 week low of $218.75 and a 52 week high of $259.92. The firm has a market cap of $67.73 billion, a P/E ratio of 48.22, a P/E/G ratio of 1.75 and a beta of 0.43.

Analysts Set New Price Targets

A number of equities analysts recently issued reports on the stock. Raymond James lowered their price objective on shares of Becton, Dickinson and Company from $275.00 to $270.00 and set an “outperform” rating for the company in a research report on Friday, August 2nd. Evercore ISI upped their price objective on shares of Becton, Dickinson and Company from $286.00 to $290.00 and gave the stock an “outperform” rating in a research report on Tuesday, October 1st. Stifel Nicolaus upped their price objective on shares of Becton, Dickinson and Company from $270.00 to $280.00 and gave the stock a “buy” rating in a research report on Friday, July 26th. Citigroup upgraded shares of Becton, Dickinson and Company from a “neutral” rating to a “buy” rating and upped their price objective for the stock from $255.00 to $275.00 in a research report on Tuesday, October 1st. Finally, StockNews.com upgraded shares of Becton, Dickinson and Company from a “hold” rating to a “buy” rating in a research report on Thursday, August 8th. Nine research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the company presently has an average rating of “Buy” and an average target price of $282.63.

About Becton, Dickinson and Company

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.